

**Authority:** Government in the Sunshine Act, 5 U.S.C. 552b.

**Laura E. Sinram,**

*Acting Secretary and Clerk of the Commission.*

[FR Doc. 2021-07093 Filed 4-1-21; 4:15 pm]

**BILLING CODE 6715-01-P**

## FEDERAL RESERVE SYSTEM

### Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)).

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than May 5, 2021.

**A. Federal Reserve Bank of San Francisco** (Sebastian R. Astrada, Director, Applications) 101 Market Street, San Francisco, California 94105-1579:

1. *Peak Bancorp, Inc., McCall, Idaho*; to become a bank holding company by acquiring Idaho First Bank, McCall, Idaho.

Board of Governors of the Federal Reserve System, March 31, 2021.

**Michele Taylor Fennell,**

*Deputy Associate Secretary of the Board.*

[FR Doc. 2021-06944 Filed 4-2-21; 8:45 am]

**BILLING CODE P**

## FEDERAL RESERVE SYSTEM

### Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington DC 20551-0001, not later than April 20, 2021.

**A. Federal Reserve Bank of Minneapolis** (Chris P. Wangen, Assistant Vice President), 90 Hennepin Avenue, Minneapolis, Minnesota 55480-0291:

1. *The Bank Share Marital Trust under the R. James Gesell Declaration of Trust dated January 13, 2000, as amended (Bank Share Marital Trust), and Andrew J. Gesell, individually and as co-trustee with Heidi R. Gesell of the Bank Share Marital Trust, all of St. Paul, Minnesota*; to acquire additional voting shares of Cherokee Bancshares, Inc., and thereby indirectly acquire additional voting shares of BankCherokee, both of St. Paul, Minnesota. Additionally, Bank Share Marital Trust; Charles R. Gesell, individually and as trustee of the Charles R. Gesell Trust Declaration under agreement dated December 30, 1999, both of Santa Rosa, California; and Peter J. Gesell, individually and as trustee of the Peter J. Gesell Trust Declaration under agreement dated December 30, 1999, both of Duluth, Minnesota; to join the Gesell Family Shareholder Group, a group acting in

concert, to acquire additional voting shares of Cherokee Bancshares, Inc., and thereby indirectly acquire voting shares of BankCherokee.

2. *DDS Trust, Preston B. Steele as trustee, both of Huron, South Dakota*; to acquire voting shares of Leackco Bank Holding Company, Inc., Huron, South Dakota, and thereby indirectly acquire voting shares of American Bank & Trust, Wessington Springs, South Dakota

**B. Federal Reserve Bank of Atlanta** (Kathryn Haney, Assistant Vice President) 1000 Peachtree Street NE, Atlanta, Georgia 30309. Comments can also be sent electronically to [Applications.Comments@atl.frb.org](mailto:Applications.Comments@atl.frb.org):

1. *Dennis Randall Aucoin, Slaughter, Louisiana*; to retain voting shares of Clinton Bancshares, Inc., and thereby indirectly retain voting shares of Landmark Bank, both of Clinton, Louisiana.

2. *Lynette Elaine Ligon, Robert David Ligon, both of Clinton, Louisiana; and Alison Leslie Ligon, Ethel, Louisiana*; to join the Ligon Family Control Group, a group acting in concert, to retain voting control of Clinton Bancshares, Inc., and thereby indirectly retain voting shares of Landmark Bank, both of Clinton, Louisiana.

Board of Governors of the Federal Reserve System, March 30, 2021.

**Michele Taylor Fennell,**

*Deputy Associate Secretary of the Board.*

[FR Doc. 2021-06888 Filed 4-2-21; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Toxic Substances and Disease Registry

[60Day-21-21EB; Docket No. ATSDR-2021-0004]

### Proposed Data Collection Submitted for Public Comment and Recommendations

**AGENCY:** Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (HHS).

**ACTION:** Notice with comment period.

**SUMMARY:** The Agency for Toxic Substances and Disease Registry (ATSDR), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction

Act of 1995. This notice invites comment on a proposed information collection project titled "Evaluating the Association between Serum Concentrations of Per- and Polyfluoroalkyl Substances (PFAS) and Symptoms and Diagnoses of Selected Acute Viral Illnesses." The proposed study will examine the relationship between PFAS serum levels and susceptibility to certain acute viral illnesses, including but not limited to COVID-19.

**DATES:** ATSDR must receive written comments on or before June 4, 2021.

**ADDRESSES:** You may submit comments, identified by Docket No. ATSDR-2021-0004 by any of the following methods:

- *Federal eRulemaking Portal:* *Regulations.gov*. Follow the instructions for submitting comments.

- *Mail:* Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS-D74, Atlanta, Georgia 30329.

*Instructions:* All submissions received must include the agency name and Docket Number. ATSDR will post, without change, all relevant comments to *Regulations.gov*.

*Please note:* Submit all comments through the Federal eRulemaking portal (*regulations.gov*) or by U.S. mail to the address listed above.

**FOR FURTHER INFORMATION CONTACT:** To request more information on the proposed project or to obtain a copy of the information collection plan and instruments, contact Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS-D74, Atlanta, Georgia 30329; phone: 404-639-7118; Email: *omb@cdc.gov*.

**SUPPLEMENTARY INFORMATION:** Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. In addition, the PRA also requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each new proposed collection, each proposed extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the collection to the OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below.

The OMB is particularly interested in comments that will help:

1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to be collected;
4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses; and
5. Assess information collection costs.

### Proposed Project

Evaluating the Impact of Per- and Polyfluoroalkyl Substances (PFAS) Exposure on Susceptibility to Viral Infection—New—Agency for Toxic Substances and Disease Registry (ATSDR).

### Background and Brief Description

Per- and poly-fluoroalkyl substances (PFAS) are a large, diverse group of thousands of chemicals. They have been used extensively in a wide range of industrial and consumer applications. Epidemiological studies have evaluated the associations between PFAS exposure and health effects in humans. Evidence from studies in occupationally exposed populations, residential populations exposed to higher levels of PFAS in drinking water, and studies in the general population suggest associations between PFAS and several health outcomes. Exposure to PFAS is nearly ubiquitous in the United States.

Epidemiological studies suggest that PFAS exposure may impact the immune system and susceptibility to viral infections; however, there is little consistency in the results of studies on PFAS exposure and infectious disease. The coronavirus disease 2019 (COVID-19) pandemic presents a unique concern and opportunity to explore this association. If PFAS affect the immune system, it is possible that they could affect susceptibility to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, or could affect severity of COVID-19.

In 2019 and 2020, the Agency for Toxic Substances and Disease Registry (ATSDR) conducted statistically based

biomonitoring PFAS exposure assessments (EAs) in eight communities that had documented exposures to PFAS in drinking water. ATSDR also supported two EAs that were designed to test the PFAS Exposure Assessment Technical Tools (PEATTT). PFAS concentrations were measured in serum collected from EA and PEATTT assessment participants, and a questionnaire was administered to gather information to characterize each individual's exposure. These communities were investigated under "Per- or Polyfluoroalkyl Substances Exposure Assessments [PFAS EAs]" (OMB Control No. 0923-0059, expiration date 06/30/2022).

During the same period, ATSDR initiated a health study at the Pease International Tradeport that included measurement of PFAS serum levels and collection of information about individual exposures in participants under "Human Health Effects of Drinking Water Exposures to Per- and Polyfluoroalkyl Substances (PFAS) at Pease International Tradeport, Portsmouth, NH (The Pease Study)" (OMB Control No. 0923-0061, expiration date 08/31/2022).

This a new two-year ATSDR information collection request (ICR) for a collaborative study between the National Center for Environmental Health (NCEH) and ATSDR. This follow-up study will recruit participants who were participated in a previous ATSDR-funded study, who have existing PFAS serum measurements, and who have given prior consent for additional contact from NCEH/ATSDR. We anticipate that the total number of participants enrolled in the NCEH/ATSDR cohorts will be around 4,075 individuals (3,300 adults and 775 children). This study will attempt to enroll the entire universe of eligible participants; therefore, our target sample size is 4,075. The cohorts have a substantial number of participants with high PFAS exposure, as well as a sufficient range of serum PFAS concentrations to allow examination of associations between the outcomes and across a wide range of PFAS exposures.

The objectives are the following: (1) To examine the association between PFAS concentrations in serum collected from existing ATSDR cohorts and the frequency of occurrence of selected syndromes (combinations of self-reported symptoms), which will be used as a proxy for viral infections; and, (2) to examine the association between PFAS concentrations in serum collected from existing ATSDR cohorts and self-reported positive test results indicating specific viral infections.

During the first three months of the two-year study period, NCEH/ATSDR will invite and consent approximately 4,075 participants (3,300 adults and 775 children) to complete a new series of questionnaires to determine whether PFAS exposure increases susceptibility to viral infections, including, but not limited to, COVID-19. Data will be

collected from those who enroll in the study through an initial paper-based questionnaire and a series of four additional questionnaires over a 12- to 14-month period. Follow-up questionnaires will be offered in two modes: Web-based and paper-based. It is estimated that 75 percent of the participants will choose the web-based

mode. Participants will also be given symptom diaries to improve recall after the initial and between each of the follow-up questionnaires.

The total time burden requested is 12,724 hours annually. There are no costs to the respondents other than their time.

#### ESTIMATED ANNUALIZED BURDEN HOURS

| Type of respondent               | Form name                                    | Number of respondents | Number of responses per respondent | Average burden per response (in hr) | Total annual burden (in hr) |
|----------------------------------|--|-----------------------|------------------------------------|-------------------------------------|-----------------------------|
| Adults .....                     | Initial Questionnaire—Adult (paper) .....    | 1,650                 | 1                                  | 30/60                               | 825                         |
|                                  | Follow up Questionnaire—Adult (paper) .....  | 412                   | 4                                  | 30/60                               | 825                         |
|                                  | Follow up Questionnaire—Adult (REDCap) ..... | 1,238                 | 4                                  | 25/60                               | 2,063                       |
|                                  | Symptom Diary .....                          | 1,650                 | 1                                  | 4                                   | 6,600                       |
| Children (7–17 years) .....      | Initial Questionnaire—Child (paper) .....    | 290                   | 1                                  | 30/60                               | 145                         |
|                                  | Follow up Questionnaire—Child (paper) .....  | 72                    | 4                                  | 30/60                               | 145                         |
|                                  | Follow up Questionnaire—Child (REDCap) ..... | 218                   | 4                                  | 25/60                               | 363                         |
|                                  | Symptom Diary .....                          | 290                   | 1                                  | 4                                   | 1,160                       |
| Parents of Children (3–6 years). | Initial Questionnaire—Child (paper) .....    | 75                    | 1                                  | 30/60                               | 38                          |
|                                  | Follow up Questionnaire—Child (paper) .....  | 24                    | 4                                  | 30/60                               | 49                          |
|                                  | Follow up Questionnaire—Child (REDCap) ..... | 74                    | 4                                  | 25/60                               | 123                         |
|                                  | Symptom Diary .....                          | 98                    | 1                                  | 4                                   | 390                         |
| Total .....                      | .....  | .....                 | .....                              | .....                               | 12,724                      |

**Jeffrey M. Zirger,**

*Lead, Information Collection Review Office, Office of Scientific Integrity, Office of Science, Centers for Disease Control and Prevention.*

[FR Doc. 2021-06882 Filed 4-2-21; 8:45 am]

**BILLING CODE 4163-70-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Board of Scientific Counselors, National Center for Health Statistics (BSC, NCHS)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Board of Scientific Counselors, National Center for Health Statistics (BSC, NCHS). This meeting is open to the public limited only by the audio (via teleconference) lines available. The public is welcome to listen to the meeting, please use the following URL [https://www.cdc.gov/nchs/about/bsc/bsc\\_meetings.htm](https://www.cdc.gov/nchs/about/bsc/bsc_meetings.htm) that points to the BSC homepage. Further information and meeting agenda will be available on the

BSC website including instructions for accessing the live meeting broadcast.

**DATES:** The meeting will be held on May 19, 2021, from 11:00 a.m. to 5:30 p.m., EDT.

**ADDRESSES:** The teleconference access is [https://www.cdc.gov/nchs/about/bsc/bsc\\_meetings.htm](https://www.cdc.gov/nchs/about/bsc/bsc_meetings.htm).

**FOR FURTHER INFORMATION CONTACT:** Sayeedha Uddin, M.D., M.P.H., Executive Secretary, NCHS/CDC, Board of Scientific Counselors, 3311 Toledo Road, Room 2627, Hyattsville, Maryland 20782, Telephone (301) 458-4303; Email [SUddin@cdc.gov](mailto:SUddin@cdc.gov).

#### SUPPLEMENTARY INFORMATION:

**Purpose:** The Board is charged with providing advice and making recommendations to the Secretary, Department of Health and Human Services; the Director, CDC; and the Director, NCHS, regarding the scientific and technical program goals and objectives, strategies, and priorities of NCHS.

**Matters To Be Considered:** The meeting agenda includes welcome remarks and a Center update by NCHS Director; presentation on National Center for Health Statistics Strategic Planning; presentation on Synthetic Data; presentation on Changes in National Health Interview Survey Data Collection During the COVID-19 pandemic; presentation on Innovation in Vital Statistics: Nowcasting

Techniques; and presentation on Division of Health Care Statistics Cloud Migration.

Agenda items are subject to change as priorities dictate.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2021-06905 Filed 4-2-21; 8:45 am]

**BILLING CODE 4163-18-P**